PMID- 33460976
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 42
IP  - 3
DP  - 2021 May-Jun
TI  - A national cancer database analysis on stereotactic body radiation therapy of 
      head and neck cancers.
PG  - 102913
LID - S0196-0709(21)00014-4 [pii]
LID - 10.1016/j.amjoto.2021.102913 [doi]
AB  - BACKGROUND: To evaluate demographic, clinicopathological, treatment factors 
      including biological effective radiation dose (BED) that influence overall 
      survival in head and neck cancer (HNC) patients treated with stereotactic body 
      radiation therapy (SBRT). METHODS: Between 2004 and 2015, 591 SBRT-treated HNC 
      patients were identified from the National Cancer Data Base. A BED using an 
      alpha/beta ratio of 10 (BED(10)), was used to compare dose fractionation of 
      different SBRT regimens. Overall survival was estimated using the Kaplan Meier 
      method, and log-rank tests were used to determine statistical significance. Cox 
      regression modeling was used to compute crude and adjusted hazard ratios (HR) 
      with 95% confidence intervals (CI). RESULTS: Median follow-up was 11.9 
      (interquartile range, 5.5 to 26.7) months. The 5-year overall survival rate was 
      15.5%. On multivariate analysis, older age, Charlson-Deyo comorbidity score >/= 1, 
      history of cancer, tumor, nodal and metastatic stage, and receiving treatment at 
      academic/research program were associated with poor survival. Compared to SBRT 
      alone, superior survival was observed with SBRT with chemotherapy, surgery with 
      SBRT, but not surgery with SBRT and chemotherapy. Improved survival was observed 
      with aa BED(10) of >/=59.5 Gy (adjusted HR 0.57, 95% CI 0.46-0.70, P < 0.0001). 
      CONCLUSIONS: Factors affecting associated with worse survival in HNC patients 
      treated with SBRT included older age, patient comorbidities, advanced tumor 
      stage, cancer history, and lower biological effective SBRT dose. LEVEL OF 
      EVIDENCE: 2b (individual cohort study).
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Park, Justin J
AU  - Park JJ
AD  - Department of Radiation Oncology, Boston Medical Center, Boston University School 
      of Medicine, Boston, MA, United States of America.
FAU - Qureshi, Muhammad M
AU  - Qureshi MM
AD  - Department of Radiation Oncology, Boston Medical Center, Boston University School 
      of Medicine, Boston, MA, United States of America.
FAU - Lam, Christa M
AU  - Lam CM
AD  - Department of Radiation Oncology, Boston Medical Center, Boston University School 
      of Medicine, Boston, MA, United States of America.
FAU - Faden, Daniel L
AU  - Faden DL
AD  - Department of Otolaryngology-Head and Neck Surgery, Mass. Eye and Ear, Mass. 
      General Hospital, Boston Medical Center, United States of America; Harvard 
      Medical School, United States of America.
FAU - Truong, Minh Tam
AU  - Truong MT
AD  - Department of Radiation Oncology, Boston Medical Center, Boston University School 
      of Medicine, Boston, MA, United States of America. Electronic address: 
      mitruong@bu.edu.
LA  - eng
PT  - Journal Article
DEP - 20210112
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Data Analysis
MH  - *Databases, Factual
MH  - Dose Fractionation, Radiation
MH  - Female
MH  - Follow-Up Studies
MH  - Head and Neck Neoplasms/mortality/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radiosurgery/*methods
MH  - Radiotherapy Dosage
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Biological effective dose
OT  - Head and neck
OT  - Radiation dose
OT  - Stereotactic body radiation therapy
OT  - Survival
EDAT- 2021/01/19 06:00
MHDA- 2021/10/13 06:00
CRDT- 2021/01/18 20:12
PHST- 2020/12/19 00:00 [received]
PHST- 2020/12/29 00:00 [accepted]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2021/01/18 20:12 [entrez]
AID - S0196-0709(21)00014-4 [pii]
AID - 10.1016/j.amjoto.2021.102913 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2021 May-Jun;42(3):102913. doi: 10.1016/j.amjoto.2021.102913. 
      Epub 2021 Jan 12.